anti-steap2/anti-cd3/anti-cd8 trispecific antibody azd6621
Generic: Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621
anti-steap2/anti-cd3/anti-cd8 trispecific antibody azd6621: 1 clinical trial tracked.
anti-steap2/anti-cd3/anti-cd8 trispecific antibody azd6621 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about anti-steap2/anti-cd3/anti-cd8 trispecific antibody azd6621, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer
Primary endpoint: Number of participants with adverse events (AE), adverse events of special interest (AESI), and serious adverse events (SAE)
InterventionalRandomizedopen52 targetStarted 2025-09Completion 2029-0326 sites · Belgium, Canada, China, Japan…AstraZeneca